The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Rapid Communications in Mass Spectrometry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12811752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

  2002cited by this paper
• Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

  2002cited by this paper
• Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

  2001cited by this paper
• Dynamics of brain-derived proteins in cerebrospinal fluid.

  2001cited by this paper
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

  2001cited by this paper
• CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

  2001cited by this paper
• Molecular Biology of Alzheimer’s Dementia and Its Clinical Relevance to Early Diagnosis and New Therapeutic Strategies

  2001cited by this paper
• Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.

  2001cited by this paper
• Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

  2000cited by this paper
• Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

  2000cited by this paper
• Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

  2000cited by this paper
• Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry

  2000cited by this paper
• The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells.

  2000cited by this paper
• The role of cholesterol in the biosynthesis of beta-amyloid.

  1999cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays.

  1999cited by this paper
• Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein.

  1999cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper
• Improved electrophoretic separation and immunoblotting of beta‐amyloid (Aβ) peptides 1–40, 1–42, and 1–43

  1997cited by this paper
• Beta-amyloid precursor protein. Location of transmembrane domain and specificity of gamma-secretase cleavage.

  1996cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• A new multiphasic buffer system for sodium dodecyl sulfate‐polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100 000–1000, and their detection with picomolar sensitivity

  1991cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Advances in sample preparation and HPLC–MS/MS methods for determining amyloid-β peptide in biological samples: a review

  2023cites this paper
• Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory

  2021cites this paper
• Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease

  2021cites this paper
• Clinical significance of fluid biomarkers in Alzheimer’s Disease

  2020cites this paper
• Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

  2019cites this paper
• Amyloid β oligomers (AβOs) in Alzheimer’s disease

  2018cites this paper
• Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer’s Disease

  2018cites this paper
• Implication of preclinical biomarkers in identification of mild cognitive impairment (MCI) and Alzheimer’s disease: Promises and future challenges

  2018cites this paper
• Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases.

  2018cites this paper
• Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

  2017cites this paper
• The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

  2017cites this paper
• Investigating Amyloid β toxicity in Drosophila melanogaster

  2017cites this paper
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016cites this paper
• Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective.

  2015cites this paper
• Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

  2015cites this paper
• Biomarkers in Sporadic and Familial Alzheimer’s Disease

  2015cites this paper
• Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome

  2014cites this paper
• Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

  2014cites this paper
• Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers

  2014cites this paper
• CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

  2014cites this paper
• Top-down peptidomics of bodily fluids

  2014cites this paper
• Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

  2012cites this paper
• Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

  2012cites this paper
• [Early evaluation of Alzheimer's disease: biomarkers and neuropsychological tests].

  2012cites this paper
• Fluid biomarkers in Alzheimer disease.

  2012cites this paper
• Molecular Plasticity Regulates Oligomerization and Cytotoxicity of the Multipeptide-length Amyloid-β Peptide Pool*

  2012cites this paper
• Distinct cerebrospinal fluid amyloid‐beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia

  2012cites this paper
• Biomarker discovery in serum/plasma using surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry.

  2012cites this paper
• A Generic Research Paradigm for Identification and Validation of Early Molecular Diagnostics and New Therapeutics in Common Disorders

  2012cites this paper
• Use of proteomic methods in the analysis of human body fluids in Alzheimer research

  2012cites this paper
• Alzheimer’s diseases: towards biomarkers for an early diagnosis

  2011cites this paper
• Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment.

  2011cites this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future

  2011cites this paper
• A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease.

  2011cites this paper
• The use of mass spectrometry to study amyloid-β peptides.

  2011cites this paper
• Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going?

  2011cites this paper
• Analysis of quality , aggregation and toxicity of amyloid beta peptide produced by JPT

  2011cites this paper
• A Window into the Heterogeneity of Human Cerebrospinal Fluid Aβ Peptides

  2011cites this paper
• Proteomic research in psychiatry

  2011cites this paper
• Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

  2010cites this paper
• CSF Biomarkers for Alzheimer's Disease Diagnosis

  2010cites this paper
• Optimization protocol for amyloid‐β peptides detection in human cerebrospinal fluid using SELDI TOF MS

  2010cites this paper
• An update on clinical proteomics in Alzheimer’s research

  2010cites this paper
• Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.

  2010cites this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cites this paper
• Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.

  2009cites this paper
• Quantitative Analysis of β-Amyloid Peptides Expressed in Human Cerebrospinal Fluid by an Improved Method of Antibody-Assisted Time-of-Flight Mass Spectrometry

  2009influential citation
• Novel T719P AβPP Mutation Unbalances the Relative Proportion of Amyloid-β Peptides

  2009cites this paper
• Rapid Etiological Classification of Meningitis by NMR Spectroscopy Based on Metabolite Profiles and Host Response

  2009cites this paper
• Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

  2009cites this paper
• [Near a biological diagnosis of Alzheimer's disease and related disorders].

  2008cites this paper
• Targeted proteomics in Alzheimer’s disease: focus on amyloid-β

  2008cites this paper
• Prediction of Alzheimer’s Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

  2008cites this paper
• Amyloid-related biomarkers for Alzheimer's disease.

  2008cites this paper
• Clinical proteomics in neurodegenerative disorders

  2008cites this paper
• Towards preventive medicine

  2008cites this paper
• Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease

  2007cites this paper
• Bioinformatics Approaches to Biomarker Discovery BIOC 218 / BMI 231 FINAL PROJECT March 2007

  2007cites this paper
• Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

  2007cites this paper
• Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations.

  2007cites this paper
• Dominance of Amyloid Precursor Protein Sequence over Host Cell Secretases in Determining β-Amyloid Profiles Studies of Interspecies Variation and Drug Action by Internally Standardized Immunoprecipitation/Mass Spectrometry

  2007cites this paper
• Conventional and Proteomic Technologies for the Detection of Early Stage Malignancies: Markers for Ovarian Cancer

  2007cites this paper
• Aspects of beta-amyloid as a biomarker for Alzheimer's disease.

  2007cites this paper
• Current state and future directions of neurochemical biomarkers for Alzheimer's disease.

  2007cites this paper
• Moderne neuropsychiatrische Diagnostik

  2007cites this paper
• Surface Enhanced Laser Desorption/Ionization (SELDI) Time-of-Flight Mass Spectrometry to Identify Patients with Chronic Obstructive Pulmonary Disease

  2006cites this paper
• The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics

  2006cites this paper
• Analysis of ligand binding by bioaffinity mass spectrometry.

  2006cites this paper
• Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease.

  2006cites this paper
• Use of surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS) to study protein expression in a rat model of cocaine withdrawal.

  2006cites this paper
• Peptide profiling of cerebrospinal fluid by mass spectrometry

  2006cites this paper
• Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.

  2006cites this paper
• Mild cognitive impairment

  2006cites this paper
• Proteomic patterns: their potential for disease diagnosis.

  2005cites this paper
• CSF proteome: a protein repository for potential biomarker identification

  2005cites this paper
• Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

  2005cites this paper
• Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides.

  2005cites this paper
• How proteomics reveals potential biomarkers in brain diseases

  2005cites this paper
• Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

  2005cites this paper
• Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease

  2005cites this paper
• Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?

  2005cites this paper
• Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia

  2005cites this paper
• CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment

  2005cites this paper
• The Application of Proteomics in Neurology

  2005influential citation
• Application of bioaffinity mass spectrometry for analysis of ligands.

  2005cites this paper
• Redox cycling of coenzyme Q9 as a new measure of plasma reducing power.

  2004cites this paper
• Biomarker discovery using molecular profiling approaches.

  2004cites this paper
• Proteomics in pathology, research and practice.

  2004cites this paper
• Homogeneous time-resolved fluorescence quenching assay (TruPoint) for nucleic acid detection.

  2004cites this paper
• Mass spectrometric analysis of protein markers for ovarian cancer.

  2004cites this paper
• Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.

  2004cites this paper
• Microarray-based approach for high-throughput genotyping of single-nucleotide polymorphisms with layer-by-layer dual-color fluorescence hybridization.

  2004cites this paper
• Clinical evaluation of an algorithm for short sample detection on a multi-analyte panel using a point-of-care analyzer.

  2004cites this paper
• Use of proteomic analysis to monitor responses to biological therapies

  2004cites this paper
• Use of computer simulation to study impact of increasing routine test volume on turnaround times of STAT samples on ci8200 integrated chemistry and immunoassay analyzer.

  2004cites this paper
• Quantitative, rapid europium(III) nanoparticle-label-based all-in-one dry-reagent immunoassay for thyroid-stimulating hormone.

  2004cites this paper
• Proteomics analysis in Alzheimer's disease: new insights into mechanisms of neurodegeneration.

  2004cites this paper
• Nucleic acid testing using surface plasmon resonance fluorescence detection.

  2004cites this paper
• Photo-removable protecting groups for in situ DNA microarray synthesis.

  2004cites this paper
• Sensitive assay for identification of methicillin-resistant Staphylococcus aureus, based on direct detection of genomic DNA by use of gold nanoparticle probes.

  2004cites this paper